What is GI Windows?
Founded in 2012 and headquartered in Westwood, Massachusetts, GI Windows is a specialized medical device company dedicated to revolutionizing anastomoses technology. The firm focuses on creating non-surgical, self-assembling devices that facilitate the connection of hollow organs, a critical component in various gastrointestinal procedures. By replacing traditional, invasive surgical techniques with more efficient, automated alternatives, GI Windows aims to improve patient outcomes, reduce recovery times, and lower overall healthcare costs. Its market position is defined by a commitment to rigorous clinical validation and the development of high-impact surgical tools that address unmet needs in the global medical device market.
How much funding has GI Windows raised?
GI Windows has raised a total of $53.4M across 2 funding rounds:
Series A
$16.4M
Series B
$37M
Series A (2020): $16.4M with participation from Sonder Capital, JC Investco, Johnson & Johnson Innovation – JJDC, Inc., and GT Healthcare Capital Partners
Series B (2024): $37M led by Rex Health Ventures, JCInvestco, and Orlando Health
Key Investors in GI Windows
Rex Health Ventures
Rex Health Ventures is an innovative platform established by UNC REX Healthcare to support and invest in healthcare technologies, aiming to enhance patient care through strategic investments in emerging entrepreneurs.
Orlando Health
Orlando Health is a comprehensive, not-for-profit healthcare organization managing a vast network of hospitals and outpatient locations, providing clinical expertise and strategic support to medical innovators.
GT Healthcare Capital Partners
GT Healthcare Capital Partners is a global venture capital firm specializing in healthcare investments, providing the necessary financial backing to scale high-potential medical technology companies.
What's next for GI Windows?
With the successful closure of its latest funding round, GI Windows is poised to transition into a critical phase of commercialization and expanded clinical trials. The influx of capital will likely be directed toward scaling manufacturing capabilities, securing regulatory clearances in key international markets, and deepening its research and development pipeline. As the company moves forward, the focus will remain on demonstrating the long-term efficacy and safety of its anastomoses technology, thereby solidifying its role as a transformative player in the surgical device industry. Strategic partnerships with major healthcare systems and continued support from institutional investors will be instrumental in navigating the complexities of the medical device regulatory environment and achieving widespread clinical adoption.
See full GI Windows company page
